Learn about early-onset Alzheimer's through real stories of hope and breakthrough treatments that are changing lives of patients diagnosed before age ...

Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

This groundbreaking finding, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, suggests that ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

In July 2024, people living with early Alzheimer’s and organizations such as the Alzheimer’s Association celebrated FDA ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

There is a potential link between Alzheimer's disease and the herpes simplex virus-1 (HSV-1), which is a common cause for ...

While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...